We have previously established in a large retrospective study that testing for microsatellite instability (MSI) in colorectal cancer (CRC) from patients aged \60 years was an effective first screen to identify individuals with Lynch syndrome (LS). From these findings, MSI and/or immunohistochemical (IHC) screening was recommended for all newly diagnosed CRC patients aged \60 years in Western Australia, regardless of family history of cancer. In the current study we evaluated the utility of routine MSI/IHC screening by diagnostic pathology laboratories for the detection of previously undiagnosed individuals and families with LS. From January 2009 to December 2010, 270 tumours were tested for MSI and for expression of MLH1, PMS2, MSH2 and MSH6 using IHC.
Introduction
Lynch Syndrome (LS) is an autosomal dominant condition caused by mutations in the mismatch repair (MMR) genes MLH1, PMS2, MSH2 and MSH6. LS accounts for approximately 1-5% [1] [2] [3] [4] of all colorectal cancers (CRC) and is also associated with an increased risk of several extra-colonic cancer types within the LS spectrum of tumours. The identification of germline mutation carriers is highly desirable as regular surveillance and early intervention has been shown to potentially detect tumours at an early stage and therefore improve the survival of these individuals [5, 6] . Furthermore, the ability to exclude at-risk members from the family of an MMR mutation carrier reduces the burden of high risk surveillance and prevention programs. The previous practice for identifying potential mutation carriers relied on accurate documentation of the family history of cancer and application of Amsterdam and Bethesda criteria [7, 8] . In the state of Western Australia, the low referral rate to the single familial cancer centre suggested these criteria were not well applied in routine clinical practice. Reasons for suboptimal application of Amsterdam and Bethesda criteria for the identification of LS have been discussed elsewhere [9] [10] [11] .
Virtually all tumours from LS patients are characterized by microsatellite instability (MSI). This distinctive molecular phenotype is almost always accompanied by the loss of expression of MMR proteins, as revealed by immunohistochemistry (IHC). We previously demonstrated in a large retrospective study that MSI testing was an effective first screen for the identification of individuals with LS in CRC patients aged \60 years [12] . Concurrent screening for a hot-spot mutation in the BRAF oncogene (V600E) allowed MSI positive cases showing loss of MLH1 and PMS2 expression by IHC to be excluded from further follow-up as potential LS cases [13, 14] . Similar to several previous studies [3, 15, 16] , the frequency of MMR gene mutation carriers amongst all CRC patients in the Western Australian population was estimated to be approximately 1% [12] .
As a result of our research, MSI and/or IHC screening was recommended for all newly diagnosed CRC patients in Western Australia aged \60 years, regardless of their family history of cancer. Since late 2008, MSI and/or IHC screening have therefore become an integral part of routine pathological assessment of CRCs in this state. Approximately 1,200 cases of CRC are diagnosed in Western Australia each year, with about 320 of these aged \60 years [17] . All MSI testing in the state is undertaken by a single, specialist molecular pathology laboratory. Follow-up assessment is undertaken by the Familial Cancer Program at Genetic Services of Western Australia (GSWA), the only state-wide clinical genetic service.
The first aim of this study was to determine whether all ''red flag'' cases, defined as showing MSI, loss of IHC staining for any of the four mismatch repair proteins and wild-type BRAF, were referred for further ascertainment to the state's single Familial Cancer Program. The second aim was to determine whether the observed number of newly identified LS cases matched the expected number of cases, assuming the prevalence of LS amongst all CRC cases is 1%.
Materials and methods

Study population
IHC of MMR protein expression is carried out by 5 major pathology laboratories in Western Australia that together diagnose over 95% of CRC cases. Although some surgeons request IHC for all patients regardless of age, routine testing is otherwise limited to patients aged \60 years with CRC who have undergone colonic resection. A small number of cases (\10% of total) are also screened by IHC at the discretion of the pathologist based on tumour morphology, or at the request of the surgeon based on clinical history. Only one pathology laboratory performed concurrent IHC and MSI testing for all \60 years old patients. All other tumour specimens that showed clear loss of MMR expression, or an equivocal result, were referred for MSI testing (Fig. 1 ) to the single laboratory offering a state-wide service.
The study cohort comprised 270 cases of CRC, including two polyps with carcinomas-in situ, that were tested for MSI. Of these, 216 were diagnosed between January 2009 and December 2010 and 54 prior to this period. Of the latter group, 17 were relatives of known GSWA clients and were retrospectively tested because they were the most appropriate family member to screen based on family history, age of diagnosis of cancer or availability of tumour tissue. The remaining 37 cases were retrospectively referred for a variety of reasons including a suspected family history of cancer, or because they were the youngest or only person available for testing in a high risk family. Ethics approval was deemed not necessary by the relevant ethics committees, who considered this work to represent an audit of routine practice.
IHC, MSI and BRAF testing
Screening for loss of expression of the MMR proteins MLH1, PMS2, MSH2 and MSH6 was carried out using IHC as described earlier [18] . MSI testing was performed using a commercial pentaplex kit as recommended by the supplier (MSI Analysis System Version 1.2, Promega, Australia). Screening for the V600E mutation in the BRAF oncogene was performed as described previously for cases that showed loss of MLH1 and/or PMS2 expression [19] . The molecular tests were carried out by a single public sector laboratory (PathWest, Sir Charles Gairdner Hospital, Nedlands, Western Australia) that has total capture of records for MSI and BRAF testing in Western Australia.
Follow-up of red flag cases
Molecular pathology test reports were sent to the treating clinician with the recommendation that red flag cases (MSI positive with wild-type BRAF) be referred to the Familial Cancer Program for follow-up. Red flag cases were also crosschecked against the GSWA database to determine whether a referral from the treating clinician had been received and whether the patient was part of a known LS family. Patients who gave consent were offered genetic counselling and germline mutation testing as described previously [12] .
Statistical analysis
All statistical analyses were carried out using SPSS version 18.0, 2009. Table 1 shows the clinico-pathological details of the study cohort. Of the 270 CRC cases referred for MSI testing, 70 (26%) were positive; however 25 of these were excluded from further follow-up due to the presence of a BRAF mutation as these are likely to represent sporadic MSI tumours. For the remaining 45 red flag cases, the corresponding IHC results were: loss of both MLH1 and PMS2 (n = 24), loss of both MSH2 and MSH6 (n = 7), loss of only one MMR protein (n = 12) and no loss of any MMR protein (n = 2). Follow-up results for the 45 red flag cases are shown in Table 2 . As of April 2011, 2 cases had died before referral and 6 cases had yet to be referred to GSWA. Thirty one cases underwent germline mutation testing, with pathogenic mutations found in 15 patients (7 in MLH1, 2 in MSH2, 3 in PMS2 and 3 in MSH6), including one case with a germline epimutation in MLH1 ( Table 3 ). All 15 cases with germline mutations showed concordant loss of the relevant MMR protein expression. Two of the 15 germline mutation carriers were members of known LS families (cases 2 and 8 in Table 3 ). Neither had undergone predictive testing, nor had they previously been diagnosed with a cancer.
Results
Discussion
The state of Western Australia has a population of approximately 2 million inhabitants. The majority of surgery for CRC and all associated laboratory tests are performed in the capital city of Perth. MSI analysis is carried out in one pathology laboratory and genetic counselling and germline testing is performed by the single, state-wide, familial cancer clinic at GSWA. To our knowledge, there are few other comparable-sized regions that are amenable to total population screening for LS in this manner. The flowchart of operations used to detect LS in Western Australia based on routine MSI and IHC testing is shown in Fig. 1 . This arrangement has facilitated the molecularbased screening for LS in the Western Australian population. Although the methylation status of hMLH1 can be used to exclude MSI cases that are sporadic in origin [20] , our experience is that screening for BRAF mutation using DNA sequencing is a more feasible approach. Numerous molecular pathology laboratories now routinely screen for KRAS mutation in advanced CRC as a marker of response to anti-EGF therapies. The KRAS test is performed using the same techniques as for BRAF mutation, thus allowing economies of scale. Beginning in 2008, MSI and/or IHC testing was recommended in Western Australia for all CRC patients aged \60 years as part of their routine pathological assessment. According to the West Australian Cancer Registry [17] , approximately 320 CRC patients in this age group are diagnosed each year and should therefore undergo screening with the aim of identifying potential LS cases. The estimated number of patients aged \60 years over the course of the 2009/2010 study period was therefore approximately 640. However, just 270 cases were tested for MSI, implying that less than half the eligible target population was screened with this molecular marker. At least some of the cases not tested for MSI were likely to have shown a normal IHC result (i.e. no loss of staining) and were therefore not referred for further testing. The selective referral of cases showing loss of MMR protein expression by IHC probably accounts for the three-fold higher incidence of MSI positive cases observed in the present cohort (25%) compared to our previous retrospective study of 1,344 consecutive CRC patients aged \60 years (7.8%) [12] .
Of the 31 red flag cases that have so far undergone germline testing, 15 (48%) were found to be mutation carriers (Tables 2 and 3 ). Assuming the untested red flag cases show a similar frequency of germline mutation, we extrapolate the total number of LS patients in our cohort to be 22, i.e. 48% of the 45 red flag cases identified. This compares favourably with the expected number of LS cases (n = 24) estimated on the basis of a 1% frequency of LS in the overall CRC population [12] , 1,200 CRCs diagnosed per year in Western Australia [17] and the 2 year study period, i.e 1% 9 1,200 9 2 = 24.
Although the expected and observed number of LS cases in this study population was similar, several issues need to be considered. First, the frequency of 1% is an estimate based on several large studies [3, 15, 16] and our earlier retrospective study of the Western Australian population [12] , but is notably lower than several other reports [4, 21, 22] . Second, we cannot be certain that all eligible cases (i.e. \60 years old) were screened by IHC. Third, no quality assurance program is yet in place for the 5 pathology services (3 public, 2 private) that perform IHC in Western Australia. The variability in IHC testing and interpretation of results between pathology laboratories has already been highlighted [23, 24] . To overcome these issues, we recommend that CRC samples from all patients aged \60 years be sent routinely for standardized MSI and/or IHC testing in an accredited laboratory and that quality assurance programs be established for both the MSI and IHC tests.
While the overall number and age distribution of CRC patients diagnosed each year in Western Australia is known, individual patient data on IHC testing could not be obtained from each institution. From this audit we cannot therefore be certain that all eligible patients were screened by IHC and, where appropriate, subsequently referred for MSI testing. In collaboration with pathology laboratories, GSWA is currently developing protocols to ensure that all eligible patients are tested at least with IHC as the initial screen and that cases showing abnormal or suspicious results are then referred for MSI testing and genetic assessment where appropriate.
Six of the 45 red flag cases (13%) were yet to be referred for genetic assessment at GSWA as of April 2011. In two cases, the attendant clinician had not received the MSI and * Likely pathogenic mutation IHC test results. Other possible reasons for failure to refer include incorrect interpretation of test results, failure to act upon the result, the clinicians' inability to encourage the patient to attend GSWA, or the patient undergoing prolonged adjuvant treatment and thus not giving priority to genetic review. The rate of consent given by red flag patients for germline testing in the current study (26/31, 84%) was significantly higher than in our earlier retrospective study (39/59, 66%; P = 0.041, Fishers' exact test) [12] , thus highlighting one of the major benefits of identifying red flag cases on a prospective basis. Of the 5 red flag patients who declined germline testing, two did not have a significant family history of cancer. A third patient and her children concluded there was no benefit to be gained from testing. The fourth patient was undergoing chemotherapy at the time and delayed the decision until the end of treatment. In the remaining case, the patient's spouse cancelled an appointment with GSWA but stated they would call at a later date. Co-incidentally, the mother of this patient was also in the study cohort (case 12 in Table 3 ) and found to have a mutation.
With regard to family history of cancer, only 4/15 (27%) and 2/15 (13%) of the mutation carriers found in this study fulfilled Amsterdam and Bethesda criteria, respectively. All of the remaining cases had some family history, but insufficient to meet these criteria. Only one red flag case was referred to GSWA based principally on their family history. Of the 45 red flag cases, 5 (11%) and 4 (9%) patients met Amsterdam and Bethesda criteria, respectively.
Although the recommended age cut-off for MSI/IHC screening in Western Australia is \60 years, 74/270 (27%) cases tested for MSI were aged 60 years or more, with the oldest being 92 years. It is unclear why these patients were tested for MSI as no specific reasons were detailed in the pathology request form. The testing of older patients was requested mainly by the same group of surgeons, who have been given feedback regarding the importance of selective screening. Amongst the older patients (C 60 years), 41 were MSI positive, however 22 (53%) of these were excluded from further follow up based on a positive BRAF mutation test result. Interestingly, of the remaining 19 BRAF wild type (red flag) older cases, four aged 64, 68, 70 and 75 years were found to be mutation carriers (Table 3) . This raises the question of whether all CRC patients should be tested for MSI and BRAF mutation, regardless of age and family history. This issue should also be addressed in terms of a cost-benefit analysis.
Another issue arising from this study is whether polyps should be screened for MSI and/or IHC. Based on family history, a sigmoid tubular adenoma with an in situ carcinoma from a 57 year old female was found to be MSI positive. Follow-up studies revealed this patient to be an MSH6 mutation carrier (case 3 in Table 3 ). While the evidence for testing polyps is equivocal [25] [26] [27] , this case demonstrates that it may be warranted if there is an indication of family history of cancer.
Western Australia now has over 2 years experience with routine, prospective MSI and/or IHC screening on CRC patients for the detection of LS. The centralization of most surgical and of all pathological and familial genetic services has allowed almost all red flag cases to be identified and tracked. A preliminary estimate from this relatively short study period suggests that most LS mutation carriers can be identified using laboratory-based screening tests. Our experience highlights the importance of collaboration and good communication between surgeons, pathologists and familial cancer services. Routine molecular testing and systematic follow-up protocols are most effective for isolated, circumscribed populations such as ours where single, state-wide molecular pathology and genetic services allow all red flag cases to be identified and monitored. However, this screening approach may be more challenging in regions where multiple molecular pathology and genetic departments service the same population. A centralized register of red flag cases and LS families would be more appropriate for such areas.
